SIEMENS HEALTHCARE DIAGNOSTICS INC. ATELLICA IM ALPHA FETOPROTEIN (AFP); KIT, TEST, ALPHA-FETOPROTEIN FOR NEURAL TUBE DEFECTS
|
Back to Search Results |
|
Model Number N/A |
Device Problem
High Test Results (2457)
|
Patient Problem
No Clinical Signs, Symptoms or Conditions (4582)
|
Event Date 08/17/2023 |
Event Type
malfunction
|
Manufacturer Narrative
|
A customer from outside the united states observed falsely elevated alpha-fetoprotein (afp) results on atellica im 1600 analyzer for multiple patient(s) samples.The initial results were not reported to the physician(s).The samples were repeated on alternate atellica im analyzers, and the results were lower.The repeat results were considered as correct by the physician(s).The interpretation of results section of the atellica im alpha-fetoprotein (afp) instructions for use (ifu) states: "results of this assay should always be interpreted in conjunction with the patient's medical history, clinical presentation, and other findings." siemens healthcare diagnostics is investigating.
|
|
Event Description
|
The customer observed falsely elevated alpha-fetoprotein (afp) results on atellica im 1600 analyzer for multiple patient(s) samples.The initial results were not reported to the physician(s).The samples were repeated on alternate atellica im analyzers, and the results were lower.The repeat results were considered as correct by the physician(s).There are no known reports of patient intervention or adverse health consequences due to the discordant elevated alpha-fetoprotein (afp) results.
|
|
Manufacturer Narrative
|
Siemens filed the initial mdr 1219913-2023-00198 on sep 15, 2023.Additional information sep 29, 2023: a customer from outside the united states observed falsely elevated alpha-fetoprotein (afp) results on atellica im 1600 analyzer for multiple patient(s) samples.The initial results were not reported to the physician(s).The samples were repeated on alternate atellica im analyzers, and the results were lower.The repeat results were considered as correct by the physician(s).On (b)(6) 2023, the customer's moving average was failing so they performed a lookback of patient samples.They identified 16 discordant results showing a positive bias versus the repeat results.The lower repeat values were believed to be correct although the difference between values did not impact the clinical interpretation.Siemens investigation included an assessment of reagent pack id's, instrument health and sample/calibration and quality control (qc) data.No related errors were posted in the event log.Afp lot 263 calibration was acceptable and biorad immunoassay plus qc lot 85330 recovered within range.Review of internal data for atellica im afp reagent lot 263 shows that all acceptance criteria was met at release.The customer is operational and they continue to report qc and patients without further concern.In section h6, the investigation finding, and investigation conclusion codes were updated.
|
|
Search Alerts/Recalls
|
|
|